Latest Health Technology at CES 2021
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
On the first MPR pod of 2021 we cover the latest COVID-19 vaccine news including admin. scheduling and production; A diagnostics test that may be giving false negative results; Bristol Myers Squibb withdraws an indication for Opdivo; And experts vote on the best diets for 2021.
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
In overall sample of men and women, metformin use was not linked to significantly reduced mortality
The FDA has granted Orphan Drug designation to UX701 (Ultragenyx Pharmaceutical) for the treatment of Wilson disease.
The FDA has approved Saxenda® (liraglutide; Novo Nordisk) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients aged 12 years and older with body weight >60kg and an initial BMI corresponding to ≥30kg/m2 for adults (obese).
The FDA has approved Imcivree™ (setmelanotide; Rhythm Pharmaceuticals) for chronic weight management in patients with obesity due to POMC, PCSK1, or LEPR deficiency.
Lumasiran is an investigational ribonucleic acid interference therapeutic that inhibits hepatic production of oxalate by targeting hydroxyacid oxidase 1.
Zokinvy works by preventing farnesylation and subsequent accumulation of progerin and progerin-like proteins in the inner nuclear membrane.
The 68-week STEP 3 trial compared the efficacy and safety of semaglutide, a glucagon-like peptide 1 receptor agonist, to placebo plus IBT.